University of Sydney School of Molecular Bioscience

TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma

Retrieved on: 
Tuesday, June 6, 2023
Survival rate, CRISPR, Brain, Cell death, Temozolomide, GBM, Gene editing, Clinical trial, Cancer, Pharmacokinetics, Transcoding, DRS, Prognosis, University of Sydney School of Molecular Bioscience, RNA, Messenger, Glioblastoma, TMZ, Professor, Animal, Patient, IRB, Michigan State University, PRR, MN, RNA interference, Frontiers Media, Therapy, Recurrence, Breast cancer, Safety, TTX, Medical imaging, Vaccine, Frontiers

Treatment of human glioblastoma cells implanted in animals with the TTX-MC138 analogue, MN-anti-miR10b, inhibited tumor cell growth and induced cell death.

Key Points: 
  • Treatment of human glioblastoma cells implanted in animals with the TTX-MC138 analogue, MN-anti-miR10b, inhibited tumor cell growth and induced cell death.
  • This study comes on the heels of preclinical studies in breast cancer demonstrating complete regressions of metastatic disease.
  • “We believe that demonstrating additional successful preclinical results with TTX-MC138 is an important step in the development process.
  • TransCode Therapeutics recently received IRB approval for a first-in-human clinical trial with TTX-MC138 in patients with advanced solid cancers.

Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine (HexaPro) Delivered Using High-Density Microarray Patch (HD-MAP)

Retrieved on: 
Tuesday, November 8, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Infection, University, Biomedical Advanced Research and Development Authority, Innovation, Skin, Omicron, Coronavirus, Department, Transport, Vaccine, COVID-19 vaccine, BARDA, Organic acid, Population, Biotechnology, University of Texas at Austin, Human, Delta, Immune system, Trial of the century, RNA transfection, University of Queensland, PLOS Medicine, COVID-19, MacLellan, Refrigeration, University of Sydney School of Molecular Bioscience, NIH, Cockrell School of Engineering, Temperature, Efficiency, Vaccination, Mouse, Development, Safety, Sale, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Chemistry, Science

Vaxxas , a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas proprietary high-density microarray patch (HD-MAP) technology.

Key Points: 
  • Vaxxas , a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas proprietary high-density microarray patch (HD-MAP) technology.
  • Vaxxas HD-MAP technology can enable cost-effective distribution without the need for extensive refrigeration, and our vaccination patch offers the potential for self-administration.
  • We are pleased to see our COVID-19 patch transition from the lab to Vaxxas for Phase I clinical trials, Dr David Muller from The University of Queensland said.
  • To create the COVID-19 vaccine candidate, Vaxxas' HD-MAP is coated with HexaPro vaccine and integrated into a single-use applicator, ready-for-vaccination.

Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches

Retrieved on: 
Wednesday, March 23, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, IIF, Temperature, Vaccination, Trial of the century, Refrigeration, Organic acid, Transport, University, Coronavirus, Skin, Vaccine, MacLellan, Cockrell School of Engineering, Biotechnology, Globe, Severe acute respiratory syndrome coronavirus 2, CEO, Omicron, United, Science Advances, Innovation, Immune system, University of Sydney School of Molecular Bioscience, BARDA, Safety, NIH, Infection, UT, COVID-19, Biomedical Advanced Research and Development Authority, Department, Development, Efficiency, Moses Austin, Pharmaceutical industry, University of Texas at Austin, Chemistry, Science, SPIKE PROTEINS AND HEXAPRO, VAXXAS’ HD-MAP TECHNOLOGY, VAXXAS

Vaxxas , a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that The University of Texas at Austin has granted Vaxxas an exclusive license to a next-generation SARS-CoV-2 spike subunit vaccine (HexaPro), for vaccination using a patch.

Key Points: 
  • Vaxxas , a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that The University of Texas at Austin has granted Vaxxas an exclusive license to a next-generation SARS-CoV-2 spike subunit vaccine (HexaPro), for vaccination using a patch.
  • We can now rapidly advance our clinical trials with our next-generation COVID-19 vaccine patch.
  • Vaxxas plans to complete a Phase 1 clinical study of its proprietary HexaPro/HD-MAP COVID-19 vaccine this year.
  • "The current pandemic has underscored the lifesaving potential of innovative technologies, and we think novel vaccination approaches clearly offer unique benefits.

BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program

Retrieved on: 
Thursday, March 10, 2022
NASDAQ, Research and development, Securities Act of 1933, B cell, Lists of diseases, Food and Drug Administration, Private Securities Litigation Reform Act, Risk, Company, Department, U.S. Securities and Exchange Commission, Stem cell, Adipocyte, Cell, Diabetes, Culture, Human, Form 10-K, Stockholm University, Pain, Securities Exchange Act of 1934, Bone marrow, Obesity, GLOBE, Patient, Degenerative disc disease, University of Sydney School of Molecular Bioscience, Security (finance), Biology, BAT, Therapy, Food, Glucose, Adult, Animal, Pharmaceutical industry, Research

The research is intended to advance the Companys understanding of the biology and role of brown fat tissue in the ability to produce heat.

Key Points: 
  • The research is intended to advance the Companys understanding of the biology and role of brown fat tissue in the ability to produce heat.
  • We are excited to enter into this research collaboration with Professor Bengtssons laboratory.
  • Heat production is an important biological property of ThermoStem and understanding its role may expand our platform technology.
  • We look forward to understanding its role and impact on BioRestoratives ThermoStem program, said Professor Bengtsson.

AIP Publishing Signs Three-Year Read & Publish Agreement with the University of Innsbruck

Retrieved on: 
Friday, February 4, 2022
View, Review of Scientific Instruments, Chemical physics, Journal of Vacuum Science and Technology, University of Sydney School of Molecular Bioscience, University, Journal of the Acoustical Society of America, Communication, Politics, Alpine Space Programme, Review, Research, Publishing, AIP, The Journal of Chemical Physics, University of Innsbruck, Journal, American Institute, American Institute of Physics, Institute of Research and Technology b-com, American Vacuum Society, Cultural conflict, Open access, Multimedia, Scientific instrument, Physics

MELVILLE, N.Y., Feb. 4, 2022 /PRNewswire/ -- AIP Publishing , a leading not-for-profit scholarly publisher in the physical sciences, has signed a Read and Publish agreement with the University of Innsbruck , Austria.

Key Points: 
  • MELVILLE, N.Y., Feb. 4, 2022 /PRNewswire/ -- AIP Publishing , a leading not-for-profit scholarly publisher in the physical sciences, has signed a Read and Publish agreement with the University of Innsbruck , Austria.
  • They also benefit from read access to most of the titles from AIP Publishing and its publishing partners.
  • "We are excited to be able to offer our researchers new opportunities through our agreement with AIP Publishing," said Erika Prnbacher.
  • "We are so pleased to offer researchers at the University of Innsbruck an opportunity to publish open access in these leading journals."

The Consortium for Top-Down Proteomics Launches a New Initiative to Develop the Human Proteoform Atlas

Retrieved on: 
Wednesday, September 29, 2021
Government, Northwestern University, Agilent Technologies, Initiative, University of Sydney School of Molecular Bioscience, Consortium, RNA, Therapy, Feinberg School of Medicine, Institute, SCIEX, University Medical Center Hamburg-Eppendorf, Environment, Disease, Life, Medical laboratory, University Medical Center, Pfizer, Chemistry, Thermo Fisher Scientific, Proteomics, Education, Protein, GLOBE, Pharmaceutical industry

This proteoform-specific information is critical to understanding the mechanisms of disease and to accelerate the development of more precise diagnostics and potential therapeutic agents.

Key Points: 
  • This proteoform-specific information is critical to understanding the mechanisms of disease and to accelerate the development of more precise diagnostics and potential therapeutic agents.
  • of Molecular Biosciences, the Feinberg School of Medicine, and Director of the Chemistry of Life Processes Institute at Northwestern University.
  • The Initiative will craft standardized representations, identifiers, and nomenclature to enable the facile sharing of data and information.
  • The Atlas will be designed to interact with other important repositories and databases, and will benefit from broad community input that will be provided by the working groups in the Initiative.